Erectile dysfunction

Internal Medicine Journal

Volumn 44, Issue 1, 2014, Pages 18-26

  Mcmahon, C G ^a  

^a Australian Centre for Sexual Health   (Australia)

Author keywords

Alprostadil; Erectile dysfunction; Intrapenile prosthesis; Phosphodiesterase type 5 inhibitor; Vacuum constriction device

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; DEVICES; DIABETES MELLITUS; ENDOCRINE DISEASE; EPIDEMIOLOGICAL DATA; ERECTILE DYSFUNCTION; HUMAN; INTRACAVERNOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE SEXUAL DYSFUNCTION; MORBIDITY; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PELVIS SURGERY; PENIS INJURY; PENIS PROSTHESIS; PEYRONIE DISEASE; PRIAPISM; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RADIOTHERAPY; SEXUAL HEALTH; UNSPECIFIED SIDE EFFECT; VACUUM CONSTRICTION DEVICE;

ALPROSTADIL; ERECTILE DYSFUNCTION; INTRAPENILE PROSTHESIS; PHOSPHODIESTERASE TYPE 5 INHIBITOR; VACUUM CONSTRICTION DEVICE;

COMORBIDITY; CORONARY DISEASE; ENDOCRINE SYSTEM DISEASES; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; MALE; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PENILE IMPLANTATION; PENIS; PHOSPHODIESTERASE 5 INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PSYCHOTHERAPY; RISK; VACUUM; VASCULAR DISEASES; VASODILATION; VASODILATOR AGENTS;

EID: 84892868972     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12325     Document Type: Article

References (23)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the massachusetts male aging study. J Urol 1994; 151: 54-61.
2. Jensen J, Lendorf A, Stimpel H, Frost J, Ibsen H, Rosenkilde P. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999; 12: 271-275.
3. Saenz De Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320: 1025-1030.
4. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-1404.
5. Chew KK. Prevalence of erectile dysfunction in community-based studies. Int J Impot Res 2004; 16: 201-202.
6. Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 2001; 55: 614-618.
7. Fedele D, Coscelli C, Santeusanio F, Bortolotti A, Chatenoud L, Colli E etal. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care 1998; 21: 1973-1977.
8. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S etal. Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: the role of the interaction between clinical and psychological factors. J Urol 2003; 169: 1422-1428.
9. Brunner GA, Pieber TR, Schattenberg S, Ressi G, Wieselmann G, Altziebler S etal. [Erectile dysfunction in patients with type I diabetes mellitus]. Wien Med Wochenschr 1995; 145: 584-586.
10. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E etal. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-649.
11. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the international index of erectile function. Urology 1999; 54: 346-351.
12. Althof SE. Quality of life and erectile dysfunction. Urology 2002; 59: 803-810.
13. Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001; 158: 1623-1630.
14. Jackson G, Rosen RC, Kloner RA, Kostis HB. The second princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006; 3: 28-36; discussion 36.
15. Melnik T, Althof S, Atallah AN, Puga ME, Glina S, Riera R. Psychosocial interventions for premature ejaculation. Cochrane Database Syst Rev 2011; CD008195.
16. Hawton K, Catalan J, Martin P, Fagg J. Long-term outcome of sex therapy. Behav Res Ther 1986; 24: 665-675.
17. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E etal. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192-199.
18. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V etal. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168 (4 Pt 1): 1332-1336.
19. Porst H, Giuliano F, Glina S, Ralph R, Adolfo R, Casabe AR etal. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351-359.
20. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004; 1: 292-300.
21. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 55: 802-815.
22. McMahon CG. Comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, prostaglandin E1 alone and a combination of all three in the management of impotence. Int J Impotence Res 1991; 3: 133-142.
23. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L etal. Peyronie's disease. J Sex Med 2004; 1: 110-115.